US00RE47249E

(19) **United States**
(12) **Reissued Patent**
Kiani et al.

(10) **Patent Number: US RE47,249 E**
(45) **Date of Reissued Patent: *Feb. 19, 2019**

(54) **ALARM SUSPEND SYSTEM**

(71) Applicant: **MASIMO CORPORATION**, Irvine, CA (US)

(72) Inventors: **Massi Joe E. Kiani**, Laguna Niguel, CA (US); **Steve L. Cebada**, Mission Viejo, CA (US); **Gregory A. Olsen**, Trabuco Canyon, CA (US)

(73) Assignee: **MASIMO CORPORATION**, Irvine, CA (US)

(*) Notice: This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/583,948**

(22) Filed: **May 1, 2017**

Related U.S. Patent Documents

Reissue of:
(64) Patent No.: **9,153,121**
Issued: **Oct. 6, 2015**
Appl. No.: **14/469,426**
Filed: **Aug. 26, 2014**

U.S. Applications:
(63) Continuation of application No. 14/036,496, filed on Sep. 25, 2013, now Pat. No. 8,847,740, which is a (Continued)

(51) **Int. Cl.**
G08B 5/22 (2006.01)
A61B 5/00 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC ***G08B 25/001*** (2013.01); ***A61B 5/1455*** (2013.01); ***A61B 5/6826*** (2013.01);
(Continued)

(58) **Field of Classification Search**
CPC ... A61B 5/1455; A61B 5/6826; A61B 5/6838; A61B 5/746; A61B 256/0276; G08B 25/001; G08B 5/22
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,639,718 A * 1/1987 Gasper G05D 21/02 210/739
4,653,498 A 3/1987 New et al.
(Continued)

FOREIGN PATENT DOCUMENTS

WO WO 2005/087097 9/2005
WO WO 2010/014743 2/2010

OTHER PUBLICATIONS

US 9,579,050, 02/2017, Al-Ali (withdrawn)
(Continued)

Primary Examiner — Ovidio Escalante
(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson & Bear, LLP

(57) **ABSTRACT**

An alarm suspend system utilizes an alarm trigger responsive to physiological parameters and corresponding limits on those parameters. The parameters are associated with both fast and slow treatment times corresponding to length of time it takes for a person to respond to medical treatment for out-of-limit parameter measurements. Audible and visual alarms respond to the alarm trigger. An alarm silence button is pressed to silence the audible alarm for a predetermined suspend time. The audible alarm is activated after the suspend time has lapsed. Longer suspend times are associated with slow treatment parameters and shorter suspend times are associated with fast treatment parameters.

24 Claims, 5 Drawing Sheets



Related U.S. Application Data

continuation of application No. 13/476,725, filed on May 21, 2012, now Pat. No. 8,547,209, which is a continuation of application No. 12/510,982, filed on Jul. 28, 2009, now Pat. No. 8,203,438.

(60) Provisional application No. 61/084,615, filed on Jul. 29, 2008.

(51) **Int. Cl.**
G08B 25/00 (2006.01)
A61B 5/1455 (2006.01)

(52) **U.S. Cl.**
CPC ***A61B 5/6838*** (2013.01); ***A61B 5/746*** (2013.01); *A61B 2560/0276* (2013.01); *G08B 5/22* (2013.01)

(58) **Field of Classification Search**
USPC .. 340/511, 517, 573.1, 539.12, 286.07, 527; 600/310, 316, 322–324, 336, 344, 507, 600/301, 320
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,960,128	A		10/1990	Gordon et al.
4,964,408	A		10/1990	Hink et al.
5,041,187	A		8/1991	Hink et al.
5,069,213	A		12/1991	Polczynski
5,111,817	A		5/1992	Clark et al.
5,163,438	A		11/1992	Gordon et al.
5,226,417	A		7/1993	Swedlow et al.
5,253,645	A		10/1993	Friedman et al.
5,253,646	A		10/1993	Delpy et al.
5,319,355	A		6/1994	Russek
5,319,363	A	*	6/1994	Welch H04Q 9/00 340/12.3
5,337,744	A		8/1994	Branigan
5,341,805	A		8/1994	Stavridi et al.
D353,195	S		12/1994	Savage et al.
D353,196	S		12/1994	Savage et al.
5,377,676	A		1/1995	Vari et al.
D359,546	S		6/1995	Savage et al.
5,431,170	A		7/1995	Mathews
D361,840	S		8/1995	Savage et al.
D362,063	S		9/1995	Savage et al.
5,452,717	A		9/1995	Branigan et al.
D363,120	S		10/1995	Savage et al.
5,456,252	A		10/1995	Vari et al.
5,479,934	A		1/1996	Imran
5,482,036	A		1/1996	Diab et al.
5,490,505	A		2/1996	Diab et al.
5,494,043	A		2/1996	O'Sullivan et al.
5,533,511	A		7/1996	Kaspari et al.
5,534,851	A		7/1996	Russek
5,561,275	A		10/1996	Savage et al.
5,562,002	A		10/1996	Lalin
5,590,649	A		1/1997	Caro et al.
5,602,924	A		2/1997	Durand et al.
5,632,272	A		5/1997	Diab et al.
5,638,816	A		6/1997	Kiani-Azarbayjany et al.
5,638,818	A		6/1997	Diab et al.
5,645,440	A		7/1997	Tobler et al.
5,685,299	A		11/1997	Diab et al.
D393,830	S		4/1998	Tobler et al.
5,743,262	A		4/1998	Lepper, Jr. et al.
5,758,644	A		6/1998	Diab et al.
5,760,910	A		6/1998	Lepper, Jr. et al.
5,769,785	A		6/1998	Diab et al.
5,782,757	A		7/1998	Diab et al.
5,785,659	A		7/1998	Caro et al.
5,791,347	A		8/1998	Flaherty et al.
5,810,734	A		9/1998	Caro et al.
5,823,950	A		10/1998	Diab et al.
5,830,131	A		11/1998	Caro et al.
5,833,618	A		11/1998	Caro et al.
5,860,919	A		1/1999	Kiani-Azarbayjany et al.
5,876,348	A		3/1999	Sugo et al.
5,890,929	A		4/1999	Mills et al.
5,904,654	A		5/1999	Wohltmann et al.
5,919,134	A		7/1999	Diab
5,934,925	A		8/1999	Tobler et al.
5,940,182	A		8/1999	Lepper, Jr. et al.
5,995,855	A		11/1999	Kiani et al.
5,997,343	A		12/1999	Mills et al.
6,002,952	A		12/1999	Diab et al.
6,005,658	A		12/1999	Kaluza et al.
6,011,986	A		1/2000	Diab et al.
6,027,452	A		2/2000	Flaherty et al.
6,036,642	A		3/2000	Diab et al.
6,045,509	A		4/2000	Caro et al.
6,050,951	A		4/2000	Friedman et al.
6,067,462	A		5/2000	Diab et al.
6,081,735	A		6/2000	Diab et al.
6,088,607	A		7/2000	Diab et al.
6,110,522	A		8/2000	Lepper, Jr. et al.
6,124,597	A		9/2000	Shehada
6,128,521	A		10/2000	Marro et al.
6,129,675	A		10/2000	Jay
6,144,868	A		11/2000	Parker
6,151,516	A		11/2000	Kiani-Azarbayjany et al.
6,152,754	A		11/2000	Gerhardt et al.
6,157,850	A		12/2000	Diab et al.
6,165,005	A		12/2000	Mills et al.
6,184,521	B1		2/2001	Coffin, IV et al.
6,190,325	B1		2/2001	Narimatsu
6,206,830	B1		3/2001	Diab et al.
6,229,856	B1		5/2001	Diab et al.
6,232,609	B1		5/2001	Snyder et al.
6,236,872	B1		5/2001	Diab et al.
6,241,683	B1		6/2001	Macklem et al.
6,253,097	B1		6/2001	Aronow et al.
6,256,523	B1		7/2001	Diab et al.
6,263,222	B1		7/2001	Diab et al.
6,278,522	B1		8/2001	Lepper, Jr. et al.
6,280,213	B1		8/2001	Tobler et al.
6,285,896	B1		9/2001	Tobler et al.
6,301,493	B1		10/2001	Marro et al.
6,317,627	B1		11/2001	Ennen et al.
6,321,100	B1		11/2001	Parker
6,325,761	B1		12/2001	Jay
6,334,065	B1		12/2001	Al-Ali et al.
6,343,224	B1		1/2002	Parker
6,349,228	B1		2/2002	Kiani et al.
6,360,114	B1		3/2002	Diab et al.
6,368,283	B1		4/2002	Xu et al.
6,371,921	B1		4/2002	Caro et al.
6,377,829	B1		4/2002	Al-Ali
6,388,240	B2		5/2002	Schulz et al.
6,397,091	B2		5/2002	Diab et al.
6,430,437	B1		8/2002	Marro
6,430,525	B1		8/2002	Weber et al.
6,463,311	B1		10/2002	Diab
6,470,199	B1		10/2002	Kopotic et al.
6,501,975	B2		12/2002	Diab et al.
6,505,059	B1		1/2003	Kollias et al.
6,515,273	B2		2/2003	Al-Ali
6,519,487	B1		2/2003	Parker
6,525,386	B1		2/2003	Mills et al.
6,526,300	B1		2/2003	Kiani et al.
6,541,756	B2		4/2003	Schulz et al.
6,542,764	B1		4/2003	Al-Ali et al.
6,553,242	B1		4/2003	Sarussi
6,580,086	B1		6/2003	Schulz et al.
6,584,336	B1		6/2003	Ali et al.
6,595,316	B2		7/2003	Cybulski et al.
6,597,932	B2		7/2003	Tian et al.
6,597,933	B2		7/2003	Kiani et al.
6,606,511	B1		8/2003	Ali et al.
6,632,181	B2		10/2003	Flaherty et al.
6,639,668	B1		10/2003	Trepagnier
6,640,116	B2		10/2003	Diab

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,643,530	B2	11/2003	Diab et al.	
6,645,155	B2	11/2003	Inukai et al.	
6,650,917	B2	11/2003	Diab et al.	
6,654,624	B2	11/2003	Diab et al.	
6,658,276	B2 *	12/2003	Kianl et al.	600/322
6,661,161	B1	12/2003	Lanzo et al.	
6,671,531	B2	12/2003	Al-Ali et al.	
6,678,543	B2	1/2004	Diab et al.	
6,684,090	B2	1/2004	Ali et al.	
6,684,091	B2	1/2004	Parker	
6,697,656	B1	2/2004	Al-Ali	
6,697,657	B1	2/2004	Shehada et al.	
6,697,658	B2	2/2004	Al-Ali	
RE38,476	E	3/2004	Diab et al.	
6,699,194	B1	3/2004	Diab et al.	
6,714,804	B2	3/2004	Al-Ali et al.	
RE38,492	E	4/2004	Diab et al.	
6,721,582	B2	4/2004	Trepagnier et al.	
6,721,585	B1	4/2004	Parker	
6,725,075	B2	4/2004	Al-Ali	
6,728,560	B2	4/2004	Kollias et al.	
6,735,459	B2	5/2004	Parker	
6,745,060	B2	6/2004	Diab et al.	
6,754,516	B2	6/2004	Mannheimer	
6,760,607	B2	7/2004	Al-Ali	
6,770,028	B1	8/2004	Ali et al.	
6,771,994	B2	8/2004	Kiani et al.	
6,792,300	B1	9/2004	Diab et al.	
6,813,511	B2	11/2004	Diab et al.	
6,816,741	B2	11/2004	Diab	
6,822,564	B2	11/2004	Al-Ali	
6,826,419	B2	11/2004	Diab et al.	
6,830,711	B2	12/2004	Mills et al.	
6,850,787	B2	2/2005	Weber et al.	
6,850,788	B2	2/2005	Al-Ali	
6,852,083	B2	2/2005	Caro et al.	
6,861,639	B2	3/2005	Al-Ali	
6,898,452	B2	5/2005	Al-Ali et al.	
6,920,345	B2	7/2005	Al-Ali et al.	
6,931,268	B1	8/2005	Kiani-Azarbayjany et al.	
6,934,570	B2	8/2005	Kiani et al.	
6,939,305	B2	9/2005	Flaherty et al.	
6,943,348	B1	9/2005	Coffin, IV	
6,950,687	B2	9/2005	Al-Ali	
6,961,598	B2	11/2005	Diab	
6,970,792	B1	11/2005	Diab	
6,979,812	B2	12/2005	Al-Ali	
6,985,764	B2	1/2006	Mason et al.	
6,993,371	B2	1/2006	Kiani et al.	
6,996,427	B2	2/2006	Ali et al.	
6,999,904	B2	2/2006	Weber et al.	
7,003,338	B2	2/2006	Weber et al.	
7,003,339	B2	2/2006	Diab et al.	
7,015,451	B2	3/2006	Dalke et al.	
7,024,233	B2	4/2006	Ali et al.	
7,027,849	B2	4/2006	Al-Ali	
7,030,749	B2	4/2006	Al-Ali	
7,039,449	B2	5/2006	Al-Ali	
7,041,060	B2	5/2006	Flaherty et al.	
7,044,918	B2	5/2006	Diab	
7,067,893	B2	6/2006	Mills et al.	
7,096,052	B2	8/2006	Mason et al.	
7,096,054	B2	8/2006	Abdul-Hafiz et al.	
7,123,950	B2	10/2006	Mannheimer	
7,132,641	B2	11/2006	Schulz et al.	
7,142,901	B2	11/2006	Kiani et al.	
7,149,561	B2	12/2006	Diab	
7,186,966	B2	3/2007	Al-Ali	
7,190,261	B2	3/2007	Al-Ali	
7,215,984	B2	5/2007	Diab	
7,215,986	B2	5/2007	Diab	
7,221,971	B2	5/2007	Diab	
7,225,006	B2	5/2007	Al-Ali et al.	
7,225,007	B2	5/2007	Al-Ali	
RE39,672	E	6/2007	Shehada et al.	
7,239,905	B2	7/2007	Kiani-Azarbayjany et al.	
7,245,953	B1	7/2007	Parker	
7,254,429	B2	8/2007	Schurman et al.	
7,254,431	B2	8/2007	Al-Ali	
7,254,433	B2	8/2007	Diab et al.	
7,254,434	B2	8/2007	Schulz et al.	
7,272,425	B2	9/2007	Al-Ali	
7,274,955	B2	9/2007	Kiani et al.	
D554,263	S	10/2007	Al-Ali	
7,280,858	B2	10/2007	Al-Ali et al.	
7,289,835	B2	10/2007	Mansfield et al.	
7,292,883	B2	11/2007	De Felice et al.	
7,295,866	B2	11/2007	Al-Ali	
7,328,053	B1	2/2008	Diab et al.	
7,332,784	B2	2/2008	Mills et al.	
7,340,287	B2	3/2008	Mason et al.	
7,341,559	B2	3/2008	Schulz et al.	
7,343,186	B2	3/2008	Lamego et al.	
D566,282	S	4/2008	Al-Ali et al.	
7,355,512	B1	4/2008	Al-Ali	
7,356,365	B2	4/2008	Schurman	
7,371,981	B2	5/2008	Abdul-Hafiz	
7,373,193	B2	5/2008	Al-Ali et al.	
7,373,194	B2	5/2008	Weber et al.	
7,376,453	B1	5/2008	Diab et al.	
7,377,794	B2	5/2008	Al-Ali et al.	
7,377,899	B2	5/2008	Weber et al.	
7,383,070	B2	6/2008	Diab et al.	
7,415,297	B2	8/2008	Al-Ali et al.	
7,428,432	B2	9/2008	Ali et al.	
7,438,683	B2	10/2008	Al-Ali et al.	
7,440,787	B2	10/2008	Diab	
7,454,240	B2	11/2008	Diab et al.	
7,467,002	B2	12/2008	Weber et al.	
7,469,157	B2	12/2008	Diab et al.	
7,471,969	B2	12/2008	Diab et al.	
7,471,971	B2	12/2008	Diab et al.	
7,483,729	B2	1/2009	Al-Ali et al.	
7,483,730	B2	1/2009	Diab et al.	
7,489,958	B2	2/2009	Diab et al.	
7,496,391	B2	2/2009	Diab et al.	
7,496,393	B2	2/2009	Diab et al.	
D587,657	S	3/2009	Al-Ali et al.	
7,499,741	B2	3/2009	Diab et al.	
7,499,835	B2	3/2009	Weber et al.	
7,500,950	B2	3/2009	Al-Ali et al.	
7,509,154	B2	3/2009	Diab et al.	
7,509,494	B2	3/2009	Al-Ali	
7,510,849	B2	3/2009	Schurman et al.	
7,526,328	B2	4/2009	Diab et al.	
7,530,942	B1	5/2009	Diab	
7,530,949	B2	5/2009	Al Ali et al.	
7,530,955	B2	5/2009	Diab et al.	
7,563,110	B2	7/2009	Al-Ali et al.	
7,596,398	B2	9/2009	Al-Ali et al.	
7,618,375	B2	11/2009	Flaherty et al.	
D606,659	S	12/2009	Kiani et al.	
7,647,083	B2	1/2010	Al-Ali et al.	
D609,193	S	2/2010	Al-Ali et al.	
D614,305	S	4/2010	Al-Ali et al.	
RE41,317	E	5/2010	Parker	
7,729,733	B2	6/2010	Al-Ali et al.	
7,734,320	B2	6/2010	Al-Ali	
7,761,127	B2	7/2010	Al-Ali et al.	
7,761,128	B2	7/2010	Al-Ali et al.	
7,764,982	B2	7/2010	Dalke et al.	
D621,516	S	8/2010	Kiani et al.	
7,791,155	B2	9/2010	Diab	
7,801,581	B2	9/2010	Diab	
7,822,452	B2	10/2010	Schurman et al.	
RE41,912	E	11/2010	Parker	
7,844,313	B2	11/2010	Kiani et al.	
7,844,314	B2	11/2010	Al-Ali	
7,844,315	B2	11/2010	Al-Ali	
7,865,222	B2	1/2011	Weber et al.	
7,873,497	B2	1/2011	Weber et al.	
7,880,606	B2	2/2011	Al-Ali	
7,880,626	B2	2/2011	Al-Ali et al.	
7,891,355	B2	2/2011	Al-Ali et al.	

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,894,868	B2	2/2011	Al-Ali et al.	
7,899,507	B2	3/2011	Al-Ali et al.	
7,899,518	B2	3/2011	Trepagnier et al.	
7,904,132	B2	3/2011	Weber et al.	
7,909,772	B2	3/2011	Popov et al.	
7,910,875	B2	3/2011	Al-Ali	
7,919,713	B2	4/2011	Al-Ali et al.	
7,937,128	B2	5/2011	Al-Ali	
7,937,129	B2	5/2011	Mason et al.	
7,937,130	B2	5/2011	Diab et al.	
7,941,199	B2	5/2011	Kiani	
7,951,086	B2	5/2011	Flaherty et al.	
7,957,780	B2	6/2011	Lamego et al.	
7,962,188	B2	6/2011	Kiani et al.	
7,962,190	B1	6/2011	Diab et al.	
7,976,472	B2	7/2011	Kiani	
7,988,637	B2	8/2011	Diab	
7,990,382	B2	8/2011	Kiani	
7,991,446	B2	8/2011	Ali et al.	
8,000,761	B2	8/2011	Al-Ali	
8,008,088	B2	8/2011	Bellott et al.	
RE42,753	E	9/2011	Kiani-Azarbayjany et al.	
8,019,400	B2	9/2011	Diab et al.	
8,028,701	B2	10/2011	Al-Ali et al.	
8,029,765	B2	10/2011	Bellott et al.	
8,036,727	B2	10/2011	Schurman et al.	
8,036,728	B2	10/2011	Diab et al.	
8,046,040	B2	10/2011	Ali et al.	
8,046,041	B2	10/2011	Diab et al.	
8,046,042	B2	10/2011	Diab et al.	
8,048,040	B2	11/2011	Kiani	
8,050,728	B2	11/2011	Al-Ali et al.	
RE43,169	E	2/2012	Parker	
8,118,620	B2	2/2012	Al-Ali et al.	
8,126,528	B2	2/2012	Diab et al.	
8,128,572	B2	3/2012	Diab et al.	
8,130,105	B2	3/2012	Al-Ali et al.	
8,145,287	B2	3/2012	Diab et al.	
8,150,487	B2	4/2012	Diab et al.	
8,175,672	B2	5/2012	Parker	
8,180,420	B2	5/2012	Diab et al.	
8,182,443	B1	5/2012	Kiani	
8,185,180	B2	5/2012	Diab et al.	
8,190,223	B2	5/2012	Al-Ali et al.	
8,190,227	B2	5/2012	Diab et al.	
8,203,438	B2 *	6/2012	Kiani et al.	340/286.07
8,203,704	B2	6/2012	Merritt et al.	
8,204,566	B2	6/2012	Schurman et al.	
8,219,172	B2	7/2012	Schurman et al.	
8,224,411	B2	7/2012	Al-Ali et al.	
8,228,181	B2	7/2012	Al-Ali	
8,229,533	B2	7/2012	Diab et al.	
8,233,955	B2	7/2012	Al-Ali et al.	
8,244,325	B2	8/2012	Al-Ali et al.	
8,255,026	B1	8/2012	Al-Ali	
8,255,027	B2	8/2012	Al-Ali et al.	
8,255,028	B2	8/2012	Al-Ali et al.	
8,260,577	B2	9/2012	Weber et al.	
8,265,723	B1	9/2012	McHale et al.	
8,274,360	B2	9/2012	Sampath et al.	
8,301,217	B2	10/2012	Al-Ali et al.	
8,306,596	B2	11/2012	Schurman et al.	
8,310,336	B2	11/2012	Muhsin et al.	
8,315,683	B2	11/2012	Al-Ali et al.	
RE43,860	E	12/2012	Parker	
8,337,403	B2	12/2012	Al-Ali et al.	
8,346,330	B2	1/2013	Lamego	
8,353,842	B2	1/2013	Al-Ali et al.	
8,355,766	B2	1/2013	MacNeish, III et al.	
8,359,080	B2	1/2013	Diab et al.	
8,364,223	B2	1/2013	Al-Ali et al.	
8,364,226	B2	1/2013	Diab et al.	
8,374,665	B2	2/2013	Lamego	
8,385,995	B2	2/2013	Al-Ali et al.	
8,385,996	B2	2/2013	Smith et al.	
8,388,353	B2	3/2013	Kiani et al.	
8,399,822	B2	3/2013	Al-Ali	
8,401,602	B2	3/2013	Kiani	
8,401,607	B2	3/2013	Mannheimer	
8,405,608	B2	3/2013	Al-Ali et al.	
8,414,499	B2	4/2013	Al-Ali et al.	
8,418,524	B2	4/2013	Al-Ali	
8,423,106	B2	4/2013	Lamego et al.	
8,428,967	B2	4/2013	Olsen et al.	
8,430,817	B1	4/2013	Al-Ali et al.	
8,437,825	B2	5/2013	Dalvi et al.	
8,455,290	B2	6/2013	Siskavich	
8,457,703	B2	6/2013	Al-Ali	
8,457,707	B2	6/2013	Kiani	
8,463,349	B2	6/2013	Diab et al.	
8,466,286	B2	6/2013	Bellott et al.	
8,471,713	B2	6/2013	Poeze et al.	
8,473,020	B2	6/2013	Kiani et al.	
8,483,787	B2	7/2013	Al-Ali et al.	
8,489,364	B2	7/2013	Weber et al.	
8,498,684	B2	7/2013	Weber et al.	
8,504,128	B2	8/2013	Blank et al.	
8,509,867	B2	8/2013	Workman et al.	
8,515,509	B2	8/2013	Bruinsma et al.	
8,523,781	B2	9/2013	Al-Ali	
8,529,301	B2	9/2013	Al-Ali et al.	
8,532,727	B2	9/2013	Ali et al.	
8,532,728	B2	9/2013	Diab et al.	
D692,145	S	10/2013	Al-Ali et al.	
8,547,209	B2 *	10/2013	Kiani et al.	340/286.07
8,548,548	B2	10/2013	Al-Ali	
8,548,549	B2	10/2013	Schurman et al.	
8,548,550	B2	10/2013	Al-Ali et al.	
8,554,297	B2	10/2013	Moon et al.	
8,560,032	B2	10/2013	Al-Ali et al.	
8,560,034	B1	10/2013	Diab et al.	
8,570,167	B2	10/2013	Al-Ali	
8,570,503	B2	10/2013	Vo et al.	
8,571,617	B2	10/2013	Reichgott et al.	
8,571,618	B1	10/2013	Lamego et al.	
8,571,619	B2	10/2013	Al-Ali et al.	
8,577,431	B2	11/2013	Lamego et al.	
8,581,732	B2	11/2013	Al-Ali et al.	
8,584,345	B2	11/2013	Al-Ali et al.	
8,588,880	B2	11/2013	Abdul-Hafiz et al.	
8,600,467	B2	12/2013	Al-Ali et al.	
8,606,342	B2	12/2013	Diab	
8,626,255	B2	1/2014	Al-Ali et al.	
8,630,691	B2	1/2014	Lamego et al.	
8,634,889	B2	1/2014	Al-Ali et al.	
8,641,631	B2	2/2014	Sierra et al.	
8,652,060	B2	2/2014	Al-Ali	
8,663,107	B2	3/2014	Kiani	
8,666,468	B1	3/2014	Al-Ali	
8,667,967	B2	3/2014	Al-Ali et al.	
8,670,811	B2	3/2014	O'Reilly	
8,670,814	B2	3/2014	Diab et al.	
8,676,286	B2	3/2014	Weber et al.	
8,682,407	B2	3/2014	Al-Ali	
RE44,823	E	4/2014	Parker	
RE44,875	E	4/2014	Kiani et al.	
8,690,799	B2	4/2014	Telfort et al.	
8,700,112	B2	4/2014	Kiani	
8,702,627	B2	4/2014	Telfort et al.	
8,706,179	B2	4/2014	Parker	
8,712,494	B1	4/2014	MacNeish, III et al.	
8,715,206	B2	5/2014	Telfort et al.	
8,718,735	B2	5/2014	Lamego et al.	
8,718,737	B2	5/2014	Diab et al.	
8,718,738	B2	5/2014	Blank et al.	
8,720,249	B2	5/2014	Al-Ali	
8,721,541	B2	5/2014	Al-Ali et al.	
8,721,542	B2	5/2014	Al-Ali et al.	
8,723,677	B1	5/2014	Kiani	
8,740,792	B1	6/2014	Kiani et al.	
8,754,776	B2	6/2014	Poeze et al.	
8,755,535	B2	6/2014	Telfort et al.	
8,755,856	B2	6/2014	Diab et al.	
8,755,872	B1	6/2014	Marinow	

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,761,850	B2	6/2014	Lamego	
8,764,671	B2	7/2014	Kiani	
8,768,423	B2	7/2014	Shakespeare et al.	
8,771,204	B2	7/2014	Telfort et al.	
8,777,634	B2	7/2014	Kiani et al.	
8,781,543	B2	7/2014	Diab et al.	
8,781,544	B2	7/2014	Al-Ali et al.	
8,781,549	B2	7/2014	Al-Ali et al.	
8,788,003	B2	7/2014	Schurman et al.	
8,790,268	B2	7/2014	Al-Ali	
8,801,613	B2	8/2014	Al-Ali et al.	
8,821,397	B2	9/2014	Al-Ali et al.	
8,821,415	B2	9/2014	Al-Ali et al.	
8,830,449	B1	9/2014	Lamego et al.	
8,831,700	B2	9/2014	Schurman et al.	
8,838,196	B2	9/2014	Mannheimer	
8,840,549	B2	9/2014	Al-Ali et al.	
8,847,740	B2 *	9/2014	Kiani et al.	340/286.07
8,849,365	B2	9/2014	Smith et al.	
8,852,094	B2	10/2014	Al-Ali et al.	
8,852,115	B2	10/2014	Muir	
8,852,994	B2	10/2014	Wojtczuk et al.	
8,868,147	B2	10/2014	Stippick et al.	
8,868,150	B2	10/2014	Al-Ali et al.	
8,870,792	B2	10/2014	Al-Ali et al.	
8,886,271	B2	11/2014	Kiani et al.	
8,888,539	B2	11/2014	Al-Ali et al.	
8,888,708	B2	11/2014	Diab et al.	
8,892,180	B2	11/2014	Weber et al.	
8,897,847	B2	11/2014	Al-Ali	
8,909,310	B2	12/2014	Lamego et al.	
8,911,377	B2	12/2014	Al-Ali	
8,912,909	B2	12/2014	Al-Ali et al.	
8,920,317	B2	12/2014	Al-Ali et al.	
8,921,699	B2	12/2014	Al-Ali et al.	
8,922,382	B2	12/2014	Al-Ali et al.	
8,929,964	B2	1/2015	Al-Ali et al.	
8,942,777	B2	1/2015	Diab et al.	
8,948,834	B2	2/2015	Diab et al.	
8,948,835	B2	2/2015	Diab	
8,956,294	B2	2/2015	McCombie et al.	
8,965,471	B2	2/2015	Lamego	
8,983,564	B2	3/2015	Al-Ali	
8,989,831	B2	3/2015	Al-Ali et al.	
8,996,085	B2	3/2015	Kiani et al.	
8,998,809	B2	4/2015	Kiani	
9,028,407	B1 *	5/2015	Bennett-Guerrero	A61B 5/1121 600/301
9,028,429	B2	5/2015	Telfort et al.	
9,037,207	B2	5/2015	Al-Ali et al.	
9,060,721	B2	6/2015	Reichgott et al.	
9,066,666	B2	6/2015	Kiani	
9,066,680	B1	6/2015	Al-Ali et al.	
9,072,474	B2	7/2015	Al-Ali et al.	
9,078,560	B2	7/2015	Schurman et al.	
9,084,569	B2	7/2015	Weber et al.	
9,095,316	B2	8/2015	Welch et al.	
9,106,038	B2	8/2015	Telfort et al.	
9,107,625	B2	8/2015	Telfort et al.	
9,107,626	B2	8/2015	Al-Ali et al.	
9,113,831	B2	8/2015	Al-Ali	
9,113,832	B2	8/2015	Al-Ali	
9,119,595	B2	9/2015	Lamego	
9,131,881	B2	9/2015	Diab et al.	
9,131,882	B2	9/2015	Al-Ali et al.	
9,131,883	B2	9/2015	Al-Ali	
9,131,917	B2	9/2015	Telfort et al.	
9,138,180	B1	9/2015	Coverston et al.	
9,138,182	B2	9/2015	Al-Ali et al.	
9,138,192	B2	9/2015	Weber et al.	
9,142,117	B2	9/2015	Muhsin et al.	
9,153,112	B1	10/2015	Kiani et al.	
9,153,121	B2	10/2015	Kiani et al.	
9,161,696	B2	10/2015	Al-Ali et al.	
9,161,713	B2	10/2015	Al-Ali et al.	
9,167,995	B2	10/2015	Lamego et al.	
9,176,141	B2	11/2015	Al-Ali et al.	
9,186,102	B2	11/2015	Bruinsma et al.	
9,192,312	B2	11/2015	Al-Ali	
9,192,329	B2	11/2015	Al-Ali	
9,192,351	B1	11/2015	Telfort et al.	
9,195,385	B2	11/2015	Al-Ali et al.	
9,211,072	B2	12/2015	Kiani	
9,211,095	B1	12/2015	Al-Ali	
9,218,454	B2	12/2015	Kiani et al.	
9,226,696	B2	1/2016	Kiani	
9,241,662	B2	1/2016	Al-Ali et al.	
9,245,668	B1	1/2016	Vo et al.	
9,259,185	B2	2/2016	Abdul-Hafiz et al.	
9,267,572	B2	2/2016	Barker et al.	
9,277,880	B2	3/2016	Poeze et al.	
9,289,167	B2	3/2016	Diab et al.	
9,295,421	B2	3/2016	Kiani et al.	
9,307,928	B1	4/2016	Al-Ali et al.	
9,323,894	B2	4/2016	Kiani	
D755,392	S	5/2016	Hwang et al.	
9,326,712	B1	5/2016	Kiani	
9,333,316	B2	5/2016	Kiani	
9,339,220	B2	5/2016	Lamego et al.	
9,341,565	B2	5/2016	Lamego et al.	
9,351,673	B2	5/2016	Diab et al.	
9,351,675	B2	5/2016	Al-Ali et al.	
9,364,181	B2	6/2016	Kiani et al.	
9,368,671	B2	6/2016	Wojtczuk et al.	
9,370,325	B2	6/2016	Al-Ali et al.	
9,370,326	B2	6/2016	McHale et al.	
9,370,335	B2	6/2016	Al-ali et al.	
9,375,185	B2	6/2016	Ali et al.	
9,386,953	B2	7/2016	Al-Ali	
9,386,961	B2	7/2016	Al-Ali et al.	
9,392,945	B2	7/2016	Al-Ali et al.	
9,397,448	B2	7/2016	Al-Ali et al.	
9,408,542	B1	8/2016	Kinast et al.	
9,436,645	B2	9/2016	Al-Ali et al.	
9,445,759	B1	9/2016	Lamego et al.	
9,466,919	B2	10/2016	Kiani et al.	
9,474,474	B2	10/2016	Lamego et al.	
9,480,422	B2	11/2016	Al-Ali	
9,480,435	B2	11/2016	Olsen	
9,492,110	B2	11/2016	Al-Ali et al.	
9,510,779	B2	12/2016	Poeze et al.	
9,517,024	B2	12/2016	Kiani et al.	
9,532,722	B2	1/2017	Lamego et al.	
9,538,949	B2	1/2017	Al-Ali et al.	
9,538,980	B2	1/2017	Telfort et al.	
9,549,696	B2	1/2017	Lamego et al.	
9,554,737	B2	1/2017	Schurman et al.	
9,560,996	B2	2/2017	Kiani	
9,560,998	B2	2/2017	Al-Ali et al.	
9,566,019	B2	2/2017	Al-Ali et al.	
9,579,039	B2	2/2017	Jansen et al.	
9,591,975	B2	3/2017	Dalvi et al.	
9,622,693	B2	4/2017	Diab	
2002/0161291	A1	10/2002	Kianl et al.	
2003/0137423	A1	7/2003	Al-Ali	
2003/0191358	A1	10/2003	MacKin et al.	
2004/0162499	A1	8/2004	Nagai et al.	
2005/0027182	A1 *	2/2005	Siddiqui	A61B 5/14532 600/365
2005/0177096	A1 *	8/2005	Bollish	A61B 5/02055 604/65
2005/0240091	A1	10/2005	Lynn	
2006/0220881	A1 *	10/2006	Al-Ali	A61B 5/14552 340/573.1
2007/0040692	A1 *	2/2007	Smith et al.	340/573.1
2007/0282478	A1	12/2007	Al-Ali et al.	
2008/0103375	A1	5/2008	Kiani	A61B 5/0002 600/323
2008/0244425	A1	10/2008	Kikin-Gil et al.	
2008/0255438	A1 *	10/2008	Saidara	A61B 5/14532 600/365
2008/0281168	A1 *	11/2008	Gibson	A61B 5/0205 600/301

(56) **References Cited**

U.S. PATENT DOCUMENTS

2009/0040874	A1*	2/2009	Rooney	A61J 7/0472 368/10
2009/0247848	A1	10/2009	Baker	
2009/0247849	A1	10/2009	McCutcheon et al.	
2009/0247984	A1	10/2009	Lamego et al.	
2009/0275813	A1	11/2009	Davis	
2009/0275844	A1	11/2009	Al-Ali	
2010/0004518	A1	1/2010	Vo et al.	
2010/0030040	A1	2/2010	Poeze et al.	
2010/0113904	A1	5/2010	Batchelder et al.	
2010/0331656	A1	12/2010	Mensinger et al.	
2011/0082711	A1	4/2011	Poeze et al.	
2011/0105854	A1	5/2011	Kiani et al.	
2011/0125060	A1	5/2011	Telfort et al.	
2011/0208015	A1	8/2011	Welch et al.	
2011/0213212	A1	9/2011	Al-Ali	
2011/0230733	A1	9/2011	Al-Ali	
2011/0237969	A1	9/2011	Eckerbom et al.	
2011/0288383	A1	11/2011	Diab	
2012/0041316	A1	2/2012	Al-Ali et al.	
2012/0046557	A1	2/2012	Kiani	
2012/0059267	A1	3/2012	Lamego et al.	
2012/0088984	A1	4/2012	Al-Ali et al.	
2012/0105233	A1	5/2012	Bobey et al.	
2012/0165629	A1	6/2012	Merritt et al.	
2012/0209082	A1	8/2012	Al-Ali	
2012/0209084	A1	8/2012	Olsen et al.	
2012/0232366	A1*	9/2012	Kiani	A61B 5/1455 600/324
2012/0283524	A1	11/2012	Kiani et al.	
2012/0296178	A1	11/2012	Lamego et al.	
2012/0303085	A1	11/2012	Vitense et al.	
2012/0319816	A1	12/2012	Al-Ali	
2013/0023775	A1	1/2013	Lamego et al.	
2013/0041591	A1	2/2013	Lamego	
2013/0046204	A1	2/2013	Lamego et al.	
2013/0060147	A1	3/2013	Welch et al.	
2013/0096405	A1	4/2013	Garfio	
2013/0096936	A1	4/2013	Sampath et al.	
2013/0243021	A1	9/2013	Siskavich	
2013/0253334	A1	9/2013	Al-Ali et al.	
2013/0267804	A1	10/2013	Al-Ali	
2013/0274572	A1	10/2013	Al-Ali et al.	
2013/0296672	A1	11/2013	O'Neil et al.	
2013/0296713	A1	11/2013	Al-Ali et al.	
2013/0324808	A1	12/2013	Al-Ali et al.	
2013/0331660	A1	12/2013	Al-Ali et al.	
2013/0331670	A1	12/2013	Kiani	
2014/0012100	A1	1/2014	Al-Ali et al.	
2014/0034353	A1	2/2014	Al-Ali et al.	
2014/0051953	A1	2/2014	Lamego et al.	
2014/0066783	A1	3/2014	Kiani et al.	
2014/0077956	A1	3/2014	Sampath et al.	
2014/0081100	A1	3/2014	Muhsin et al.	
2014/0081175	A1	3/2014	Telfort	
2014/0100434	A1	4/2014	Diab et al.	
2014/0114199	A1	4/2014	Lamego et al.	
2014/0120564	A1	5/2014	Workman et al.	
2014/0121482	A1	5/2014	Merritt et al.	
2014/0127137	A1	5/2014	Bellott et al.	
2014/0129702	A1	5/2014	Lamego et al.	
2014/0135588	A1	5/2014	Al-Ali et al.	
2014/0142401	A1	5/2014	Al-Ali et al.	
2014/0163344	A1	6/2014	Al-Ali	
2014/0163402	A1	6/2014	Lamego et al.	
2014/0166076	A1	6/2014	Kiani et al.	
2014/0171763	A1	6/2014	Diab	
2014/0180038	A1	6/2014	Kiani	
2014/0180154	A1	6/2014	Sierra et al.	
2014/0180160	A1	6/2014	Brown et al.	
2014/0187973	A1	7/2014	Brown et al.	
2014/0213864	A1	7/2014	Abdul-Hafiz et al.	
2014/0266790	A1	9/2014	Al-Ali et al.	
2014/0275808	A1	9/2014	Poeze et al.	
2014/0275835	A1	9/2014	Lamego et al.	
2014/0275871	A1	9/2014	Lamego et al.	
2014/0275872	A1	9/2014	Merritt et al.	
2014/0276115	A1	9/2014	Dalvi et al.	
2014/0288400	A1	9/2014	Diab et al.	
2014/0309507	A1	10/2014	Baker, Jr.	
2014/0316217	A1	10/2014	Purdon et al.	
2014/0316218	A1	10/2014	Purdon et al.	
2014/0316228	A1	10/2014	Blank et al.	
2014/0323825	A1	10/2014	Al-Ali et al.	
2014/0323897	A1	10/2014	Brown et al.	
2014/0323898	A1	10/2014	Purdon et al.	
2014/0330092	A1	11/2014	Al-Ali et al.	
2014/0330098	A1	11/2014	Merritt et al.	
2014/0330099	A1	11/2014	Al-Ali et al.	
2014/0336481	A1	11/2014	Shakespeare et al.	
2014/0357966	A1	12/2014	Al-Ali et al.	
2015/0005600	A1	1/2015	Blank et al.	
2015/0011907	A1	1/2015	Purdon et al.	
2015/0012231	A1	1/2015	Poeze et al.	
2015/0025406	A1	1/2015	Al-Ali	
2015/0032029	A1	1/2015	Al-Ali et al.	
2015/0038859	A1	2/2015	Dalvi et al.	
2015/0045637	A1	2/2015	Dalvi	
2015/0051462	A1	2/2015	Olsen	
2015/0080754	A1	3/2015	Purdon et al.	
2015/0087936	A1	3/2015	Al-Ali et al.	
2015/0094546	A1	4/2015	Al-Ali	
2015/0097701	A1	4/2015	Al-Ali et al.	
2015/0099950	A1	4/2015	Al-Ali et al.	
2015/0099951	A1	4/2015	Al-Ali et al.	
2015/0099955	A1	4/2015	Al-Ali et al.	
2015/0101844	A1	4/2015	Al-Ali et al.	
2015/0106121	A1	4/2015	Muhsin et al.	
2015/0112151	A1	4/2015	Muhsin et al.	
2015/0116076	A1	4/2015	Al-Ali et al.	
2015/0126830	A1	5/2015	Schurman et al.	
2015/0133755	A1	5/2015	Smith et al.	
2015/0141781	A1	5/2015	Weber et al.	
2015/0165312	A1	6/2015	Kiani	
2015/0196237	A1	7/2015	Lamego	
2015/0216459	A1	8/2015	Al-Ali et al.	
2015/0230755	A1	8/2015	Al-Ali et al.	
2015/0233722	A1	8/2015	Al-Ali	
2015/0245773	A1	9/2015	Lamego et al.	
2015/0245794	A1	9/2015	Al-Ali	
2015/0257689	A1	9/2015	Al-Ali et al.	
2015/0272514	A1	10/2015	Kiani et al.	
2015/0351697	A1	12/2015	Weber et al.	
2015/0351704	A1	12/2015	Kiani et al.	
2015/0359429	A1	12/2015	Al-Ali et al.	
2015/0366472	A1	12/2015	Kiani	
2015/0366507	A1	12/2015	Blank	
2015/0374298	A1	12/2015	Al-Ali et al.	
2015/0380875	A1	12/2015	Coverston et al.	
2016/0000362	A1	1/2016	Diab et al.	
2016/0007930	A1	1/2016	Weber et al.	
2016/0029932	A1	2/2016	Al-Ali	
2016/0045118	A1	2/2016	Kiani	
2016/0051205	A1	2/2016	Al-Ali et al.	
2016/0058338	A1	3/2016	Schurman et al.	
2016/0058347	A1	3/2016	Reichgott et al.	
2016/0066823	A1	3/2016	Kind et al.	
2016/0066824	A1	3/2016	Al-Ali et al.	
2016/0066879	A1	3/2016	Telfort et al.	
2016/0072429	A1	3/2016	Kiani et al.	
2016/0081552	A1	3/2016	Wojtczuk et al.	
2016/0095543	A1	4/2016	Telfort et al.	
2016/0095548	A1	4/2016	Al-Ali et al.	
2016/0103598	A1	4/2016	Al-Ali et al.	
2016/0113527	A1	4/2016	Al-Ali	
2016/0143548	A1	5/2016	Al-Ali	
2016/0166182	A1	6/2016	Al-Ali et al.	
2016/0166183	A1	6/2016	Poeze et al.	
2016/0166188	A1	6/2016	Bruinsma et al.	
2016/0166210	A1	6/2016	Al-Ali	
2016/0192869	A1	7/2016	Kiani et al.	
2016/0196388	A1	7/2016	Lamego	
2016/0197436	A1	7/2016	Barker et al.	
2016/0213281	A1	7/2016	Eckerbom et al.	

(56) **References Cited**

U.S. PATENT DOCUMENTS

2016/0228043	A1	8/2016	O'Neil et al.
2016/0233632	A1	8/2016	Scruggs et al.
2016/0234944	A1	8/2016	Schmidt et al.
2016/0270735	A1	9/2016	Diab et al.
2016/0283665	A1	9/2016	Sampath et al.
2016/0287090	A1	10/2016	Al-Ali et al.
2016/0287786	A1	10/2016	Kiani
2016/0296169	A1	10/2016	McHale et al.
2016/0310052	A1	10/2016	Al-Ali et al.
2016/0314260	A1	10/2016	Kiani
2016/0324486	A1	11/2016	Al-Ali et al.
2016/0324488	A1	11/2016	Olsen
2016/0327984	A1	11/2016	Al-Ali et al.
2016/0328528	A1	11/2016	Al-Ali et al.
2016/0331332	A1	11/2016	Al-Ali
2016/0367173	A1	12/2016	Dalvi et al.
2017/0007134	A1	1/2017	Al-Ali et al.
2017/0007190	A1	1/2017	Al-Ali et al.
2017/0007198	A1	1/2017	Al-Ali et al.
2017/0014084	A1	1/2017	Al-Ali et al.
2017/0021099	A1	1/2017	Al-Ali et al.
2017/0027456	A1	2/2017	Kinast et al.
2017/0042488	A1	2/2017	Muhsin
2017/0055847	A1	3/2017	Kiani et al.
2017/0055851	A1	3/2017	Al-Ali
2017/0055882	A1	3/2017	Al-Ali et al.
2017/0055887	A1	3/2017	Al-Ali
2017/0055896	A1	3/2017	Al-Ali et al.
2017/0079594	A1	3/2017	Telfort et al.
2017/0086723	A1	3/2017	Al-Ali et al.

OTHER PUBLICATIONS

Rheineck-Leyssius, MD, et al., "Advanced Pulse Oximeter Signal Processing Technology Compared to Simple Averaging. I. Effect on Frequency of Alarms in the Operating Room", Journal of Clinical Anesthesia, The Netherlands, May 1999, vol. 11, pp. 192-195.

Cust, AE, et al., "Alarm settings for the Marquette 8000 pulse oximeter to prevent hyperoxic and hypoxic episodes", Journal Paediatric Child Health, 1999, vol. 35, pp. 159-162.

Lawless, Stephen T., "Crying wolf: False alarms in a pediatric intensive care unit", Critical Care Medicine, 1994, vol. 22, No. 6, pp. 981-985.

Informal Expert Report of Dr. Stephen Barker, Lead Case No. 16-05968-LT11, executed Feb. 10, 2017.

Impact of Clinical Alarms on Patient Safety, ACCE Healthcare Technology Foundation, 2006, 20 pages.

Taenzer, M.D., Andreas, "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers", The American Society of Anesthesiologists, Inc., Feb. 2010, vol. 112, No. 2, pp. 282-287.

Stefanescu, MD MSc, Beatrice, "Improved Filtering of Pulse Oximeter Monitoring Alarms in the Neonatal ICU: Bedside Significance", Respiratory Care, Jan. 2016, vol. 61, No. 1, pp. 85-89.

Rheineck-Leyssius, A.T., et al., "Influence of pulse oximeter lower alarm limit on the incidence of hypoxaemia in the recovery room", British Journal of Anaesthesia, 1997, vol. 79, pp. 460-464.

Rheineck-Leyssius, MD, Aart, et al., "Influence of Pulse Oximeter Settings on the Frequency of Alarms, and Detection of Hypoxemia", Journal of Clinical Monitoring and Computing, 1998, vol. 14, pp. 151-156.

Pan, MD., Peter, "Intraoperative Pulse Oximetry: Frequency and Distribution of Discrepant Data", Journal of Clinical Monitoring and Computing, Nov./Dec. 1994, vol. 6, pp. 491-495.

Graham, Kelly, et al., Monitor Alarm Fatigue: Standardizing Use of Physiological Monitors and Decreasing Nuisance Alarms, American Journal of Critical Care, Jan. 2010, vol. 19, No. 1, pp. 27-37.

Barker, PhD, MD, Steven, "'Motion-Resistant' Pulse Oximetry: A Comparison of New and Old Models" Department of Anesthesiology, 2002, vol. 95, pp. 967-972.

National Patient Safety Goals Effective Jan. 1, 2015, Hospital Accreditation Program, The Joint Commission, Jan. 2015, pp. 1-17.

Brostowicz, Heather, et al. Oxygen saturation monitoring in the Neonatal Intensive Care Unit (NICU): Evaluation of a new alarm management, Journal of Neonatal-Perinatal Medicine 3, 2010, pp. 135-139.

Kowalczyk, Liz, "Patient alarms often unheard, unheeded" The Boston Globe, Feb. 13, 2011, in 5 pages.

Taenzer, Andreas, et al., "Postoperative Monitoring—The Dartmouth Experience", The Official Journal of the Anesthesia Patient Safety Foundation, Spring-Summer 2012, vol. 27, No. 1, pp. 1-28.

Tobin, Martin, "Principles and Practice of Intensive Care Monitoring", 1998, in 30 pages.

Severinghaus, M.D., John, et al., Pulse Oximeter Failure Thresholds in Hypotension and Vasoconstriction, Anesthesiology, Sep. 1990, vol. 73, No. 3, pp. 532-537.

Pologe, Jonas A., "Pulse Oximetry: Technical Aspects of Machine Design", International Anesthesiology Clinics, Advances in Oxygen Monitoring, Fall, 1987, vol. 25, No. 3, pp. 137-153.

Tremper, Ph.D., Kevin et al., "Pulse Oximetry", Medical Intelligence Article, Anesthesiology, Jan. 1989, vol. 70, No. 1, pp. 98-108.

Bosque, PhD, Elena, "Symbiosis of nurse and machine through fuzzy logic: Improved specificity of a neonatal pulse oximeter alarm", Dec. 1995, vol. 18, Issue 2, pp. 67-75.

Paine, MPH, Christine, et al., "Systematic review of physiologic monitor alarm characteristics and pragmatic interventions to reduce alarm frequency" J Hosp Med., Feb. 2017, vol. 11, No. 2, pp. 136-144.

Top 10 Technology Hazards for 2012, Guidance Article, Nov. 2011, www.ecri.org, pp. 358-373.

Top 10 Technology Hazards for 2013, Health Devices, ECRI Institute, Nov. 2012, reprinted from vol. 41, Issue 11, in 25 pages.

Top 10 Health Technology Hazards for 2014, Health Devices, ECRI Institute, Nov. 2013, www.ecri.org/2014hazards, 1 page.

Masimo Advanced Alarm Performance: An Evidence-Based Approach to Reduce False Alarms and Nuisance Alarms, 2010, in 8 pages.

International Search Report for PCT/US2009/052146, dated Dec. 15, 2009.

International Preliminary Report on Patentability and Written Opinion for PCT/US2009/052146 dated Feb. 10, 2011.

* cited by examiner



FIG. 1


200
201
205
209
280
282
284
286
288
DISPLAY
ALARMS
USER I/O
ALARM SILENCE
Display Driver
Audio Driver
I/O
270
260
INSTRUMENT MANAGER
ALARM SUSPEND FIRMWARE
250
DIGITAL SIGNAL PROCESSOR
220
A/D CONVERTER
240
D/A CONVERTERS
210
FRONT-END SIGNAL CONDITIONER
230
EMITTER DRIVERS
211
MONITOR
208
DETECTORS
10
206
λ1, λ2, ... λn
EMITTERS
SENSOR

FIG. 2


300
MEASURED PARAMETERS
312
LIMITS
314
COMPARATOR
310
OUT-OF LIMIT
318
ALARMS
340
342
PRIORITY
328
SILENCE
322
TIMER
320
DURATION
324
SYSTEM STATUS
332
FAILURE MODES
334
COMPARATOR
330
SYSTEM FAILURE
338

FIG. 3


400
within-limit
410
412
ALARM OFF
no data
out-of-limit
414
424
within-limit
439
no data
ALARM ON
420
within-limit
428
override
436
silence
422
expired
434
ALARM SUSPEND
438
430
t<duration
432

FIG. 4


560
500
Suspend
502
512
SpO_2
sec.
30
60
514
90
120
522
SpCO
mln.
2
5
524
10
15
520
510
$= = 85$ $\%SpO_2$
140
50
BPM
99
71
501

FIG. 5

ALARM SUSPEND SYSTEM

Matter enclosed in heavy brackets [ ] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue; a claim printed with strikethrough indicates that the claim was canceled, disclaimed, or held invalid by a prior post-patent action or proceeding.

CROSS-REFERENCE TO RELATED APPLICATIONS

This [application] is *an application for reissue of U.S. Pat. No. 9,153,121, issued on Oct. 6, 2015 and titled "Alarm Suspend System," which is* a continuation of U.S. patent application Ser. No. 14/036,496, filed Sep. 25, 2013 and titled "Alarm Suspend System," which is a continuation of U.S. patent application Ser. No. 13/476,725, filed May 21, 2012 and titled "Alarm Suspend System," which is a continuation of U.S. patent application Ser. No. 12/510,982 filed Jul. 28, 2009 and titled "Alarm Suspend System," which claims priority benefit under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Ser. No. 61/084,615, filed Jul. 29, 2008, titled "Alarm Management System;" *more than one reissue application has been filed for the reissue of U.S. Pat. No. 9,153,121, including U.S. patent application Ser. No. 15/583,948 (the present application), U.S. patent application Ser. No. 15/583,922, and U.S. patent application Ser. No. 15/583,935.*["] All of the above-referenced applications are hereby incorporated by reference herein in their entireties.

BACKGROUND

Pulse oximetry for measuring constituents of circulating blood has achieved acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios. A pulse oximeter generally includes a two-wavelength optical sensor applied to a patient, a monitor for processing sensor signals and displaying results and a patient cable electrically interconnecting the sensor and the monitor. The monitor typically provides a numerical readout of physiological parameters such as oxygen saturation (SpO_2) and pulse rate (PR). Advanced physiological monitors utilize multiple wavelength sensors and enhanced measurement capabilities to provide readouts of additional parameters, such as carboxyhemoglobin (HbCO), methemoglobin (HbMet) and total hemoglobin (Hbt).

Pulse oximeters capable of reading through motion induced noise are disclosed in at least U.S. Pat. Nos. 6,770,028, 6,658,276, 6,650,917, 6,157,850, 6,002,952, 5,769,785 and 5,758,644; low noise pulse oximetry sensors are disclosed in at least U.S. Pat. Nos. 6,088,607 and 5,782,757; all of which are assigned to Masimo Corporation, Irvine, Calif. ("Masimo") and are incorporated by reference herein.

Physiological monitors and corresponding multiple wavelength optical sensors are described in at least U.S. patent application Ser. No. 11/367,013, filed Mar. 1, 2006 and titled Multiple Wavelength Sensor Emitters and U.S. patent application Ser. No. 11/366,208, filed Mar. 1, 2006 and titled Noninvasive Multi-Parameter Patient Monitor, both assigned to Masimo Laboratories, Irvine, Calif. (Masimo Labs) and both incorporated by reference herein.

Further, physiological monitoring systems that include low noise optical sensors and pulse oximetry monitors, such as any of LNOP® adhesive or reusable sensors, SofTouch™ sensors, Hi-Fi Trauma™ or Blue™ sensors; and any of Radical®, SatShare™, Rad-9™, Rad-5™, Rad-5v™ or PPO+™ Masimo SET® pulse oximeters, are all available from Masimo. Physiological monitoring systems including multiple wavelength sensors and corresponding noninvasive blood parameter monitors, such as Rainbow™ adhesive and reusable sensors and RAD-57™ and Radical-7™ monitors for measuring SpO_2, pulse rate (PR), perfusion index (PI), pleth variability index (PVI), signal quality, HbCO and HbMet among other parameters are also available from Masimo.

SUMMARY OF THE INVENTION

Monitor alarms are triggered by out-of-limit parameters and system failures, the latter including monitor or sensor failures or improper sensor placement, to name a few. Alarms can be visual, audible or both. Alarms can also have different levels of priority, which are reflected in the type of visual and audible alarms. In an embodiment, parameters exceeding limits such as low SpO_2, high HbCO, high HbMet and low and high BPM trigger high priority alarms. System failures due to sensor off, no sensor or defective sensor also trigger high priority alarms. Parameters exceeding limits such as high SpO_2, low and high PI, low and high PVI, for example, trigger medium priority alarms. Parameters exceeding limits such as low HbCO and low HbMet along with a system low battery indication are examples of low priority alarms.

An audible alarm may be temporarily suspended by pressing an alarm silence button so as to prevent unnecessary disturbance to the patient and distraction of the caregiver. During alarm suspension, visual alarms remain active. If an alarm condition persists after a predetermined alarm suspend period, the audible alarm resumes. The alarm suspend period is typically long enough to give a caregiver sufficient time to intervene with appropriate patient treatment yet short enough to ensure that patient health is not endangered if intervention is ineffective. For conventional pulse oximetry, an alarm suspend may be, for example, a maximum of 120 seconds.

Alarm suspension on advanced blood parameter monitors is problematic. With conventional pulse oximetry, treatment for abnormal parameter measurements can be quickly applied and a patient response is typically fast. For example, a treatment for low oxygen saturation is the application of an oxygen mask or an increase in oxygen flow. By contrast, the duration of treatment for parameters measured by advanced monitors is highly dependent on the alarm-triggering parameter. For example, the treatment for high methemoglobin is the injection of methylene blue, and the patient response to such an injection is slow. When patient treatment time exceeds the maximum alarm suspend period, an audible alarm will constantly reactivate. Thus, a single alarm suspend duration for all parameters is inadequate to cope with the many different types of parameters measured by advanced monitors.

One aspect of an alarm suspend system for silencing the alarms is an alarm trigger responsive to any of various parameters and predetermined limits corresponding to the parameters, where the parameters are partitioned according to treatment time, i.e. the relative length of time it takes for a person to respond to medical treatment for a parameter measurement outside of the predetermined limits. An

audible alarm is responsive to the alarm trigger. An alarm silence button is actuated so as to suspend the audible alarm. A timer tracks the duration of the suspended alarm and is initiated by actuation of an alarm silence button. The timer retriggers the audible alarm after the timed duration has lapsed/expired. In an embodiment, a long duration suspend time is associated with slow treatment parameters and a short duration suspend time is associated with fast treatment parameters. Fast treatment parameters may include, for example, parameters relating to normal blood hemoglobin constituents and slow treatment parameters may include parameters relating to abnormal blood hemoglobin constituents.

In various embodiments, a short duration suspend time is less than or equal to about two minutes and a long duration suspended time is greater than about two minutes. A default duration associated with the fast treatment parameters is about two minutes and a default duration associated with the slow treatment parameters is about fifteen minutes. The alarm suspend system may also have an alarm suspend override responsive to a predetermined unit change in the parameter triggering a suspended alarm. The override results in reactivation of the suspended alarm. A physiological monitor having an alarm suspend system may also have a pop-up window that appears on the monitor display in response to actuation of the silence button, where the pop-up window presents a choice of alarm suspend durations.

Another aspect of an alarm suspend system is a partition of measured parameters into at least a first group and a second group. An audible alarm is triggered if at least one parameter is outside of predetermined limits. The audible alarm is suspended in response to a silence request. A first duration is associated with the first group and a second duration is associated with the second group. The audible alarm is reactivated after at least one of the first duration and the second duration. The first duration may be set so as to generally correspond to a first range of treatment times for the first group of parameters. Likewise, the second duration may be set so as to generally correspond to a second range of treatment times for the second group of parameters, where the first range of treatment times and the second range of treatment times are non-overlapping.

In various embodiments, suspended audible alarms are overridden if the triggering parameter has greater than a predetermined unit change before the suspended alarm expires according to either the first duration or the second duration. The first and second groups are defined in relation to normal hemoglobin measurements abnormal hemoglobin measurements, respectively. The first duration is set to be less than or equal to two minutes and the second duration is set to be greater than two minutes, with default durations of about two minutes corresponding to the first group and about fifteen minutes corresponding to the second group. In an embodiment, a pop-up window for a monitor display is constructed and the first duration and the second duration are selected from a range of durations presented within the pop-up window.

A further aspect of an alarm suspend system deactivates an audible alarm for one of a short duration and a long duration according to the alarm-triggering parameter. A first group of parameters is associated with the short duration and a second group of parameters is associated with the long duration. The first group and the second group are partitioned according to a fast treatment time and a short treatment time associated with the parameters. An override reactivates the audible alarm if the trigger parameter changes more than a predetermine amount during the corresponding duration. In various embodiments, the first group comprises parameters related to the measurement of normal hemoglobin and the second group comprises parameters related to the measurement of abnormal hemoglobin. The long duration is greater than about 120 seconds and the short duration is less than or equal to about 120 seconds. A pop-up window for the display allows selection of the long duration and the short duration in response to the silence button.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. **1** is a perspective view of a physiological measurement system utilizing an alarm suspend system;

FIG. **2** is a detailed block diagram of a physiological measurement system utilizing an alarm suspend system;

FIG. **3** is a flow diagram of an alarm suspend system embodiment;

FIG. **4** is a state diagram of an alarm suspend system embodiment; and

FIG. **5** is an illustration of an alarm suspend pop-up window.

DETAILED DESCRIPTION

FIG. **1** illustrates a physiological measurement system **100** that utilizes an alarm suspend system. The physiological measurement system **100** has a noninvasive sensor **105** attached to a tissue site **10**, a physiological monitor **101**, and an interface cable **109** interconnecting the monitor **101** and the sensor **105**. The physiological measurement system **100** may incorporate pulse oximetry in addition to advanced features, such as a multiple wavelength sensor and advanced processes for determining physiological parameters other than or in addition to those of pulse oximetry, such as carboxyhemoglobin, methemoglobin and total hemoglobin, as a few examples.

The monitor **101** has a front panel **110** providing a display **120**, touch keys **130**, controls **140**, a speaker **150**, a sensor port **160** and status indicators **170**. The display **120** shows parameter readouts, limits and waveforms among other items. The display **120** also has touch key icons **122** that indicate touch key **130** functions. The speaker **150** provides an audible alarm in response to physiological measurements that violate preset conditions, such as an out-of-limit parameter, as well as system failures, such as a low battery condition. The controls **140** include an alarm silence button **144** that is pressed to temporarily suspend out-of-limit parameter alarms and system alarms, such as low battery. The display **120** provides visual alarms, which include a bell-shaped alarm status indicator **124** that illuminates during an alarm condition and parameter readouts **210** and limits **220** that flash when parameters are out-of-limit. Status indicators **170** also provide visual alarms. When there are multiple alarm conditions, the parameter displays **202** indicate parameters with the highest alarm priority. Touch keys **130** and corresponding icons **122** include an alarm menu access button for setting alarm conditions, such as high or low alarm limits for SpO_2, HbCO, HbMet, PR and PI. The alarm silence button **144** is pressed to temporarily suspend audible alarms. Advantageously, an alarm suspend system provides a parameter-dependent variation in the alarm suspend duration, as described below, utilizing a common silence button or other suspend initiator.

FIG. **2** illustrates a physiological measurement system **200** including a physiological monitor **201**, a sensor **205** and an interface cable **209**. The sensor **205** is attached to a tissue site, such as a finger **10**, and includes a plurality of emitters

206 irradiating the tissue site 10 with multiple wavelengths of light. The sensor 205 also includes one or more detectors 208 capable of detecting the light after attenuation by the tissue site 10. The sensor 205 transmits optical radiation at wavelengths other than or including the red and infrared wavelengths utilized in pulse oximeters. The monitor 201 inputs a corresponding sensor signal 211 and determines the relative concentrations of blood constituents other than or in addition to the "normal" blood hemoglobin constituents HbO_2 and Hb, including "abnormal" blood hemoglobin constituents HbCO, HbMet and blood related parameters such as fractional oxygen saturation, total hemoglobin and blood glucose to name a few.

As shown in FIG. 2, the monitor 201 has a front-end signal conditioner 210, an A/D converter 220, emitter drivers 230, D/A converters 240 and a digital signal processor ("DSP") 250. In general, the emitter drivers 230 convert digital control signals, via the D/A converters 240, into analog drive signals capable of driving the sensor emitters 206. The front-end signal conditioner 210 converts, via the A/D converter 220, composite analog intensity signal(s) from light sensitive detector(s) 208 into digital data input to the DSP 250. The emitter drivers 230 and front-end signal conditioner 210 communicate with the sensor 205 via the interface cable 209.

Also shown in FIG. 2, the monitor 201 has an instrument manager 260 and a user interface 280. The user interface 280 includes one or more displays 282, alarms 284 and user input/output (I/O) 286. The instrument manager 260 communicates with the DSP 250 to receive parameter data and to present that data on the display 282. The instrument manager 260 may also store and display historical or trending data related to one or more of the measured parameters or combinations of the measured parameters. The instrument manager 260 also controls audible and visual alarms and indicators 284. The instrument manager 260 responds to user-actuated keys and communicates with external devices via various I/O ports 286. Further, the instrument manager 260 executes alarm suspend firmware 270 so as to respond to an alarm silence button press 288, as described in detail with respect to FIGS. 3-4.

FIG. 3 generally illustrates an alarm suspend system 300. Alarm triggers include system failures 338 and out-of-limit parameters 318. Triggered alarms 340 may be audible, visual or both, and may vary according to priority 342. Audible alarms may be generated by a monitor front-panel-mounted speaker 150 (FIG. 1) and may vary in loudness, pitch and sound pattern. Visual alarms may include parameter labels, parameter numerics, symbols and status lights, which can flash and vary in color.

As shown in FIG. 3, measured parameters 312 are compared 310 to default or user-specified limits 314. An out-of-limit condition 318 triggers an alarm 340. An alarm suspend 328 is user-initiated by a silence request 322. This may be a press of a silence button 144 (FIG. 1) on a monitor front panel 110 (FIG. 1). In an embodiment, the alarm suspend 328 silences audible alarms and modifies the display of visual alarms. The alarm suspend 328 is based on a timer 320, which ends the alarm suspend 328 after a predetermined duration 324. The duration 324 may be a function of the out-of-limit parameter 312. In an advantageous embodiment, the duration 324 relates to, or is a function of, the treatment time for the alarm-triggering parameter so as to avoid nuisance alarms while maintaining alarm integrity.

FIG. 4 illustrates an alarm suspend embodiment 400 that operates independently for each measured parameter that can trigger an alarm. An alarm is initially off 410. The alarm remains off as long as the parameter is within its set limits 412. If a parameter is measured outside of its set limits 414, an alarm is triggered 420. The alarm may audible, visual or both audible and visual. A user can request to silence the alarm by pressing an alarm silence button 144 (FIG. 1), for example. The silence request 422 suspends the alarm 430 which turns off audible alarms but, in an embodiment, does not deactivate visual alarms. The audible alarm remains suspended 430 for a predetermined duration 432. When the suspend duration has passed, the alarm suspend expires 434 and audible alarms are once again activated 420. The alarm remains on 428 until the triggering parameter is within limits 424 or a user once again requests silence 422. The alarm suspend 430 deactivates if the measured parameter becomes within limits 438, such as when the patient condition improves, or if no physiological data is detected 439, such as no sensor, sensor off, no cable or malfunctioning sensor situations, to name a few. Also, if the measured parameter changes during the alarm suspend 430 by a sufficient out-of-limit amount, an override 436 reactivates the audible alarms 420.

In an alarm suspend system embodiment, parameters are classified according to the typical time it takes for medical treatment to transition an out-of-limit measurement to a within-limit measurement. Suspend durations 324 (FIG. 3) are set accordingly. For example, in a two-tier embodiment, relatively slow treatment parameters, such as HbMet, HbCO, Hbt and PVI, are assigned relatively long suspend durations. Similarly, relatively fast treatment parameters, such as SpO_2 and PR, are assigned relatively short suspend durations. In an embodiment, the alarm suspend duration is adjustable for each individual parameter, including 2, 5, 10, 15, 20, 25 and 30 minutes for slow treatment parameters, with a default of 15 minutes; and 30, 60, 90 and 120 seconds for fast treatment parameters, with a default of 120 seconds. These alarm features are only active when alarm limits have been set. Other alarm features apply to both slow treatment and fast treatment parameters. For example, an alarm delay of 0, 5, 10 or 15 seconds applies to all enabled parameters.

In an embodiment, an override 436 occurs if slow treatment parameters such as HbCO, HbMet or PVI increase or Hbt decreases by a certain unit change during the alarm suspend duration. The unit change is adjustable for each parameter, such as from 1-15 in increments of 1. TABLE 1 shows a default embodiment of override unit changes for these parameters.

TABLE 1

Override Unit Changes for Selected Parameters

Parameter	Unit Change	Direction
HbCO	5	Increase
HbMet	2	Increase
Hbt	2	Decrease
PVI	OFF	Increase

FIG. 5 illustrates an alarm suspend window 500 that provides a "pop-up" display so that a monitor user may manually enter an alarm suspend duration. The alarm suspend window 500 appears as a portion of a monitor display 501, such as the front panel display 120 (FIG. 1) described above. The pop-up window 500 responds to a suspend request, such as a silence button 144 (FIG. 1) press. The alarm suspend window 500 has a window identifier 502 and one or more parameter subsections 510, 520. Each param-

eter subsection **510**, **520** has a parameter identifier **512**, **522** and corresponding suspend duration options **514**, **524**. In an embodiment, specific suspend times are selected via monitor touch keys **130** (FIG. **1**) as guided by corresponding touch key icons **560**. Selected suspend times are highlighted or otherwise identified and entered, also via a touch key **130** (FIG. **1**). In an alternative embodiment, the monitor display is a touch screen and alarm suspend times are directly entered by a finger press on a specific duration "virtual button" **514**, **524**. Once one or more suspend durations are entered, the pop-up window **500** disappears from the display **501**. The alarm suspend window **500** advantageously allows a user to quickly choose an appropriate alarm suspend duration for the situation at hand, rather than relying on a predetermined or default duration.

An alarm suspend system is described above with respect to alarms triggered by measured parameters and limits associated with those measured parameters. Limits may correspond to levels of a measured parameter, such as a percentage oxygen saturation to name but one example. Limits may also correspond to trends of a measured parameter, such as a rate-of-change of oxygen saturation, for example. Limits may also correspond to patterns in a measured parameter or a comparison of one measured parameter with another measured parameter, as further examples.

An alarm suspend system is described above with respect to a two-tier grouping of parameters, such as slow treatment and fast treatment parameters and alarm suspend durations associated with those groups. Groupings of parameters with respect to alarm suspend durations may be multi-tier, such as slow, medium and fast treatment parameters, to name but one example.

An alarm suspend system has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims that follow. One of ordinary skill in the art will appreciate many variations and modifications.

What is claimed is:

1. A physiological measurement system comprising:

a *noninvasive* physiological sensor **[**including: a plurality of light emitting diodes**]** configured to **[**transmit wavelengths of light onto a tissue site of a patient; and at least one detector configured to measure an indication of the wavelengths of light after attenuation by tissue of the patient and**]** *be positioned on a patient and* output a signal responsive **[**of the attenuated light**]** *to a physiological condition of the patient*; and

one or more processors in communication with the *noninvasive* physiological sensor, the one or more processors configured to *electronically*:

determine a measurement of a physiological parameter based at least in part upon the signal;

determine whether an alarm condition exists by determining whether an activation threshold has been satisfied by the measurement of the physiological parameter;

[receive, from a user, an indication of**]** *access an alarm hold initiator for* a parameter-specific alarm **[**suspension**]** *hold* period of time corresponding to the physiological parameter, the parameter-specific alarm **[**suspension**]** *hold* period of time being **[**selected from**]** *one of* a plurality of parameter-specific alarm **[**suspension**]** *hold* periods of time, the parameter-specific alarm **[**suspension**]** *hold* period of time being different from at least one other parameter-specific alarm **[**suspension**]** *hold* period of time corresponding to at least one other physiological parameter *for which the one or more processors are configured to determine at least one measurement*;

[activate an alarm in response to determining that an alarm activation threshold has been satisfied by the physiological parameter measurement;

receive**]** *determine that the alarm hold initiator indicates to hold an indication of* an alarm **[**suspension indication**]** *for the alarm condition*; **[**and**]**

in response to **[**receiving**]** *determining that the alarm hold initiator indicates to hold the indication of* the alarm **[**suspension indication**]**, **[**suspend**]** *hold the indication of* the alarm for the **[**indicated**]** parameter-specific alarm **[**suspension**]** *hold* period of time*; and subsequent to the parameter-specific alarm hold period of time passing, activate the indication of the alarm while the measurement of the physiological parameter satisfies the activation threshold.*

2. The physiological measurement system of claim **1**, wherein the one or more processors are further configured to:

provide a user interface to the user including at least a plurality of user-selectable elements, each of the *plurality of user*-selectable elements corresponding to one of the plurality of parameter-specific alarm **[**suspension**]** *hold* periods of time.

3. The physiological measurement system of claim **2**, wherein providing the user interface further includes:

constructing a pop-up window for a display; and

displaying the plurality of user-selectable elements in the pop-up window.

4. The physiological measurement system of claim **3**, wherein the plurality of user-selectable elements are configured to allow a user to select a specific one of the plurality of parameter-specific alarm **[**suspension**]** *hold* periods of time.

5. The physiological measurement system of claim **4**, wherein **[**the**]** *a* selected parameter-specific alarm **[**suspension**]** *hold* period of time is selected by selection of one of the plurality of user-selectable elements.

6. The physiological measurement system of claim **1**, wherein the one or more processors are further configured to:

associate **[**the**]** *a* selected parameter-specific *alarm hold* period of time **[**is**]** with the physiological parameter.

7. The physiological measurement system of claim **6**, wherein the selected parameter-specific *alarm hold* period of time is stored in a memory device in communication with the one or more processors.

8. The physiological measurement system of claim **1**, wherein the one or more processors are further configured to:

determine a *measurement of a* second physiological parameter **[**measurement**]** based at least in part upon the signal*, the second physiological parameter being different from the physiological parameter*;

determine whether a second alarm condition exists by determining whether a second activation threshold has been satisfied by the measurement of the second physiological parameter;

[receive, from the user,**]** *access* a second **[**indication of**]** *alarm hold initiator for* a second parameter-specific alarm **[**suspension**]** *hold* period of time corresponding to the second physiological parameter, the second parameter-specific alarm **[**suspension**]** *hold* period of time being **[**selected from**]** *one of* a second plurality of parameter-specific alarm **[**suspension**]** *hold* periods of time*, the second parameter-specific alarm hold period*

of time being different from the parameter-specific alarm hold period of time corresponding to the physiological parameter;

[activate a second alarm in response to determining a second alarm activation threshold has been satisfied by the second physiological parameter measurement] *determine that the second alarm hold initiator indicates to hold an indication of a second alarm for the second alarm condition*; [and]

in response to [receiving] *determining that the second alarm hold initiator indicates to hold the indication of* the *second* alarm [suspension indication], [suspend] *hold the indication of* the second alarm for the [indicated] second parameter-specific alarm [suspension] *hold* period of time*; and*

subsequent to the second parameter-specific alarm hold period of time passing, activate the indication of the second alarm while the measurement of the second physiological parameter satisfies the second activation threshold.

9. The physiological measurement system of claim **8**, wherein the one or more processors are further configured to:

provide a user interface to the user including at least a first plurality of user-selectable elements and a second plurality of user-selectable elements, wherein each of the first plurality of user-selectable elements corresponds to one of the plurality of parameter-specific alarm [suspension] *hold* periods of time, and each of the second plurality of user-selectable element corresponds to one of the second plurality of parameter-specific alarm [suspension] *hold* periods of time.

10. The physiological measurement system of claim **9**, wherein the one or more processors are further configured to:

construct a pop-up window for a display; and

display both the first and second plurality of user-selectable elements in the pop-up window.

11. The physiological measurement system of claim **10**, wherein [the] *a* selected *first* parameter-specific alarm [suspension] *hold* period of time is selected by selection of one of the first plurality of user-selectable elements, and [the] *a* selected second parameter-specific alarm [suspension] *hold* period of time is selected by selection of one of the second plurality of user-selectable elements.

12. The physiological measurement system of claim **11**, wherein the at least one of the [first] plurality of parameter-specific alarm [suspension] *hold* periods of time is different from any of the second plurality of parameter-specific alarm [suspension] *hold* periods of time.

13. [An] *A* method comprising:

measuring a *first* physiological parameter *and a second physiological parameter* using a patient monitoring device, the patient monitoring device including a processor and a memory device [configured to store a parameter-specific alarm suspension period of time];

[receiving] *accessing*, from [a user] *the memory device*, [an indication of] *a first alarm hold initiator for* a *first* parameter-specific alarm [suspension] *hold* period of time corresponding to the *first* physiological parameter *and a second alarm hold initiator for a second parameter-specific alarm hold period of time corresponding to the second physiological parameter*, [the parameter-specific alarm suspension period of time being selected from a plurality of parameter-specific alarm suspension periods of time,] the *first* parameter-specific alarm [suspension] *hold* period of time being different from [at least one other] *the second* parameter-specific alarm [suspension] *hold* period of time [corresponding to at least one other physiological parameter; activating an alarm in response to determining an alarm activation threshold has been satisfied by the physiological parameter measurement];

[receiving an] *determining that the first alarm hold initiator indicates to hold a first indication of a first* alarm [suspension indication] *for a first alarm condition for the first physiological parameter*; [and]

in response to [receiving] *determining that the first alarm hold initiator indicates to hold the first indication of* the *first* alarm [suspension indication], [suspending] *holding the first indication of* the *first* alarm for the [indicated] *first* parameter-specific alarm [suspension] *hold* period of time*; and*

subsequent to the first parameter-specific alarm hold period of time passing, activating the first indication of the first alarm.

14. The method of claim **13**, wherein the *first* alarm includes an audible component and a visual component, and wherein [suspending] *holding the first indication of* the *first* alarm comprises [suspending] *holding* the audible component and not [suspending] *holding* the visual component.

15. The method of claim **13** further comprising:

providing a user interface to the user including at least a plurality of user-selectable elements, each of the *plurality of user*-selectable elements corresponding to one of [the] *a* plurality of parameter-specific alarm [suspension] *hold* periods of time,

wherein the plurality of parameter-specific alarm hold periods of time comprise the first parameter specific alarm hold period of time.

16. The method of claim **15** further comprising:

constructing a pop-up window for a display; and

displaying the plurality of user-selectable elements in the pop-up window.

17. The method of claim **16**, wherein [the] *a* selected parameter-specific alarm [suspension] *hold* period of time is selected by selection of one of the plurality of user-selectable elements.

18. A physiological measurement system comprising:

a physiological sensor [means for outputting] *configured to output* a signal responsive to a [noninvasive measurement of attenuated light transmitted through a tissue site] *physiological condition* of a patient;

a memory configured to store a first alarm activation threshold; and

[a processing means] *one or more processors* in communication with the physiological sensor [means] and configured to:

determine a *first* measurement of [a] *the first measured* physiological parameter based at least in part upon the signal;

determine whether a first alarm condition exists by determining whether the first alarm activation threshold has been satisfied by the first measurement of the first measured physiological parameter;

[receive, from a user, an indication of a] *access a first alarm hold initiator for a first* parameter-specific alarm [suspension] *hold* period of time corresponding to the *first measured* physiological parameter, [the parameter-specific alarm suspension period of time being selected from a plurality of parameter-specific alarm suspension periods of time,] the *first* parameter-specific alarm [suspension] *hold* period of time being different from [at least one other] *a*

second parameter-specific alarm [suspension] *hold* period of time corresponding to [at least one other] *a second measured* physiological parameter *for which the one or more processors are configured to determine a second measurement*;

[activate an alarm in response to determining an alarm activation threshold has been satisfied by the physiological parameter measurement;

receive an] *determine that the first alarm hold initiator indicates to hold activation of a first* alarm [suspension indication] *for the first alarm condition*; [and]

in response to [receiving] *determining that the first alarm hold initiator indicates to hold activation of* the *first* alarm [suspension indication], [suspend] *hold activation of* the *first* alarm for the [indicated] *first* parameter-specific alarm [suspension] *hold* period of time*; and*

activate the first alarm.

19. The physiological measurement system of claim **18**, wherein the [processing means is] *one or more processors are* further configured to:

determine [a] *the* second [physiological parameter] measurement based at least in part upon the signal;

determine whether a second alarm condition exists by determining whether a second alarm activation threshold has been satisfied by the second measurement;

[receive, from the user,] *access* a second [indication of a] *alarm hold initiator for the* second parameter-specific alarm [suspension] *hold* period of time [corresponding to the second physiological parameter, the second parameter-specific alarm suspension period of time being selected from a second plurality of parameter-specific alarm suspension periods of time; activate a second alarm in response to determining a second alarm activation threshold has been satisfied by the second physiological parameter measurement];

determine that the second alarm hold initiator indicates to hold activation of a second alarm for the second alarm condition; and

in response to [receiving] *determining that the second alarm hold initiator indicates to hold activation of* the *second* alarm [suspension indication], [suspend] *hold activation of* the second alarm for the [indicated] second parameter-specific alarm [suspension] *hold* period of time.

20. The physiological measurement system of claim **19**, wherein the [processing means is] *one or more processors are* further configured to:

provide a user interface to the user including at least a first plurality of user-selectable elements and a second plurality of user-selectable elements, wherein each of the first plurality of user-selectable elements corresponds to one of [the] *a first* plurality of parameter-specific alarm [suspension] *hold* periods of time, and each of the second plurality of user-selectable [element] *elements* corresponds to one of [the] *a* second plurality of parameter-specific alarm [suspension] *hold* periods of time,

wherein the first plurality of parameter-specific alarm hold periods of time comprise the first parameter-specific alarm hold period of time, and the second plurality of parameter-specific alarm hold periods of time comprise the second parameter-specific alarm hold period of time.

21. The physiological measurement system of claim **20**, wherein [the] *a* selected *first* parameter-specific alarm [suspension] *hold* period of time is selected by selection of one of the first plurality of user-selectable elements, and [the] *a* selected second parameter-specific alarm [suspension] *hold* period of time is selected by selection of one of the second plurality of user-selectable elements.

22. The physiological measurement system of claim **21**, wherein at least one of the first plurality of parameter-specific alarm [suspension] *hold* periods of time is different from any of the second plurality of parameter-specific alarm [suspension] *hold* periods of time.

23. The physiological measurement system of claim 1, wherein the one or more processors are further configured to modify a visual indicator for the parameter-specific alarm hold period of time.

24. The physiological measurement system of claim 1, wherein the physiological parameter comprises one of an oxygen saturation, a pulse rate, a perfusion index, a pleth variability index, a carboxyhemoglobin, a methemoglobin, or a total hemoglobin.

* * * * *

(12) **INTER PARTES REVIEW CERTIFICATE** (2597th)
United States Patent
Kiani et al.

(10) **Number: US RE47,249 K1**
(45) **Certificate Issued: Feb. 18, 2022**

(54) **ALARM SUSPEND SYSTEM**

(71) Applicant: **MASIMO CORPORATION**

(72) Inventors: **Massi Joe E. Kiani; Steve L. Cebada; Gregory A. Olsen**

(73) Assignee: **MASIMO CORPORATION**

Trial Number:

IPR2020-01033 filed Jun. 3, 2020

Inter Partes Review Certificate for:

Patent No.: **RE47,249**
Issued: **Feb. 19, 2019**
Appl. No.: **15/583,948**
Filed: **May 1, 2017**

The results of IPR2020-01033 are reflected in this inter partes review certificate under 35 U.S.C. 318(b).

INTER PARTES REVIEW CERTIFICATE
U.S. Patent RE47,249 K1
Trial No. IPR2020-01033
Certificate Issued Feb. 18, 2022

AS A RESULT OF THE INTER PARTES REVIEW PROCEEDING, IT HAS BEEN DETERMINED THAT:

Claims **1-24** are cancelled.

* * * * *